Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 6/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL772937 | 0.80 | EGFR (0.50) | TYRALOX5MEN1MAPTKMT2A | |
| SCHEMBL51397 | 0.79 | TYR (0.71) | TYRALOX5MEN1MAPTKMT2A | |
| SCHEMBL1397158 | 0.79 | TYR (1.00) | TYRALOX5MEN1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL19834718 | 0.78 | TYR (0.62) | TYRALOX5MEN1MAPTKMT2A | |
| SCHEMBL647503 | 0.77 | TYR (0.68) | TYRALOX5MEN1MAPTKMT2A | |
| SCHEMBL3749697 | 0.76 | TYR (0.60) | TYRALOX5MEN1MAPTKMT2A | |
| SCHEMBL639119 | 0.76 | POLB (0.57) | TYRMEN1MAPTKMT2ACYP3A4 | |
| SCHEMBL40375 | 0.75 | TYR (0.65) | TYRALOX5MEN1MAPTKMT2A | |
| SCHEMBL21917009 | 0.75 | TYR (0.65) | TYRALOX5MEN1MAPTKMT2A | |
| SCHEMBL10912123 | 0.75 | TYR (0.65) | TYRALOX5MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| EP-2245031-B1 | 6,9-DISUBSTITUTED PURINE DERIVATIVES AND THEIR USE AS COSMETICS AND COSMETIC COMPOSITIONS | INST OF EX BOTANY ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2014-02-26 | — | — | EP | disclosed |
| US-8575182-B2 | 6, 9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions | Institute of Experimental Botany, Academy of Sciences of the Czeck Republic (CZ) | 2013-11-05 | — | — | US | disclosed |
| US-8552013-B2 | Heterocyclic compounds based on N6-substituted adenine, methods of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2013-10-08 | — | — | US | disclosed |
| US-8492391-B2 | Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containing these derivatives | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2013-07-23 | — | — | US | disclosed |
| US-20120070512-A1 | Substituted 6-(2-hydroxybenzylamino)purine Derivatives, Their Use as Medicaments and Compositions Containing These Derivatives | BIOPATTERNS, S.R.O (CZ) | 2012-03-22 | — | — | US | disclosed |
| US-20110230503-A1 | 6, 9-Disubstituted Purine Derivatives and Their Use as Cosmetics and Cosmetic Compositions | SZUCOVA LUCIE | 2011-09-22 | — | — | US | disclosed |
| US-7960397-B2 | 6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions | INSTITUTE OF EXPERIMENTAL BOTANY, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2011-06-14 | — | — | US | disclosed |
| US-20090170879-A1 | 6,9-Disubstituted Purine Derivatives and Their Use as Cosmetics and Cosmetic Compositions | SZUCOVA LUCIE | 2009-07-02 | — | — | US | disclosed |
| US-20080014227-A1 | HETEROCYCLIC COMPOUNDS BASED ON N6-SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | USTAV EXPERIMENTALNI BOTANIKY AKADEMIE VED CESKE REPUBLIKY (CZ) | 2008-01-17 | — | — | US | disclosed |
| US-7279482-B2 | Heterocyclic compound based on N6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | Ústav experimentálni botaniky Akademie ved Ceské republiky (CZ) | 2007-10-09 | — | — | US | disclosed |
| US-20050043328-A1 | Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | USTAV EPERIMENTALNI BOTANIKY AKADEMI VED CESKE REPUBILIKY (CZ) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | TYR 1423/4885ALOX5 849/4885MEN1 3276/4885 |
| US-20080014227-A1 | HETEROCYCLIC COMPOUNDS BASED ON N6-SUBSTITUTED ADENINE, METHODS OF THEIR PREPARATION, THEIR USE FOR PREPARATION OF DRUGS, COSMETIC PREPARATIONS AND GROWTH REGULATORS, PHARMACEUTICAL PREPARATIONS, COSMETIC PREPARATIONS AND GROWTH REGULATORS CONTAINING THESE COMPOUNDS | TYMP, CCNB1, CCNA2 | TYR 301/4885ALOX5 2639/4885MEN1 1447/4885 |
| US-20050043328-A1 | Heterocyclic compound based on n6-substituted adenine, methods, of their preparation, their use for preparation of drugs, cosmetic preparations and growth regulators, pharmaceutical preparations, cosmetic preparations and growth regulators containing these compounds | ATIC, UMPS, CCNB1 | TYR 651/4885ALOX5 2713/4885MEN1 574/4885 |
| US-20120070512-A1 | Substituted 6-(2-hydroxybenzylamino)purine Derivatives, Their Use as Medicaments and Compositions Containing These Derivatives | CDK6, CCNI, CDK2 | TYR 3233/4885ALOX5 655/4885MEN1 4355/4885 |
| US-20090170879-A1 | 6,9-Disubstituted Purine Derivatives and Their Use as Cosmetics and Cosmetic Compositions | P2RY6, UMPS, PNP | TYR 88/4885ALOX5 502/4885MEN1 4520/4885 |
| US-20110230503-A1 | 6, 9-Disubstituted Purine Derivatives and Their Use as Cosmetics and Cosmetic Compositions | P2RY6, UMPS, PNP | TYR 88/4885ALOX5 502/4885MEN1 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.